Not just any partnership, but specifically the Roche partnership in charge of the INFORM-n program that has captured investors’ attention as though it were the only industry-wide attempt at an all-oral HCV regimen. This is a classic case of market inefficiency, IMHO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”